Noven Pharms Inc patents expiration
1. Combipatch patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5474783 | NOVEN PHARMS INC | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Dec, 2012
(11 years ago) | |
| US5958446 | NOVEN PHARMS INC | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Dec, 2012
(11 years ago) | |
| US6024976 | NOVEN PHARMS INC | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Jan, 2014
(10 years ago) | |
| US5656286 | NOVEN PHARMS INC | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Aug, 2014
(9 years ago) | |
Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE ingredient
Market Authorisation Date: 07 August, 1998
Treatment: NA
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
COMBIPATCH family patents
2. Daytrana patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5958446 | NOVEN PHARMS INC | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Dec, 2012
(11 years ago) | |
| US6348211 | NOVEN PHARMS INC | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
Sep, 2018
(5 years ago) | |
| US6210705 | NOVEN PHARMS INC | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
Sep, 2018
(5 years ago) | |
| US9034370 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic polymers |
Oct, 2025
(1 year, 5 months from now) | |
| US8632802 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic polymers |
Oct, 2025
(1 year, 5 months from now) | |
| US9668981 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic based polymers |
Oct, 2025
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 29, 2013 |
Drugs and Companies using METHYLPHENIDATE ingredient
Market Authorisation Date: 06 April, 2006
Treatment: For the treatment of attention deficit hyperactivity disorder (adhd); Method for transdermally delivering a drug to a user in need thereof
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
DAYTRANA family patents
3. Xelstrym patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8591941 | NOVEN PHARMS INC | Transdermal drug delivery device including an occlusive backing |
Oct, 2025
(1 year, 5 months from now) | |
| US9034370 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic polymers |
Oct, 2025
(1 year, 5 months from now) | |
| US8632802 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic polymers |
Oct, 2025
(1 year, 5 months from now) | |
| US9474722 | NOVEN PHARMS INC | Compositions and methods for transdermal delivery of amphetamine |
Oct, 2033
(9 years from now) | |
| US9456993 | NOVEN PHARMS INC | Compositions and methods for transdermal delivery of amphetamine |
Oct, 2033
(9 years from now) | |
| US11559501 | NOVEN PHARMS INC | Transdermal amphetamine compositions with low levels of carbamate |
Jan, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 22, 2025 |
Drugs and Companies using DEXTROAMPHETAMINE ingredient
Market Authorisation Date: 22 March, 2022
Treatment: A method of treating attention deficit hyperactivity disorder by administering a transdermal composition containing amphetamine
Dosage: SYSTEM;TRANSDERMAL
XELSTRYM family patents